BMP action in the pituitary: Its possible role in modulating somatostatin sensitivity in pituitary tumor cells

Molecular and Cellular Endocrinology

Volumn 349, Issue 2, 2012, Pages 105-110

  Otsuka, Fumio ^a   Tsukamoto, Naoko ^a   Miyoshi, Tomoko ^a   Iwasaki, Yasumasa ^b   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Bone morphogenetic protein; Corticotrope; Lactotrope; Pituitary adenoma; Somatostatin

Indexed keywords

ANGIOPEPTIN; BONE MORPHOGENETIC PROTEIN; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; OCTREOTIDE; PASIREOTIDE; PROLACTIN; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 2; DRUG DERIVATIVE;

AUTOCRINE EFFECT; CLINICAL EFFECTIVENESS; CORTICOTROPIN RELEASE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; HORMONE SENSITIVITY; HUMAN; HYPOPHYSIS ADENOMA; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROLACTIN RELEASE; PROLACTINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; ACTH SECRETING CELL; ADENOMA; ANIMAL; DRUG EFFECT; HYPOPHYSIS TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROLACTIN SECRETING CELL;

ADENOMA; ADRENOCORTICOTROPIC HORMONE; ANIMALS; AUTOCRINE COMMUNICATION; BONE MORPHOGENETIC PROTEINS; CORTICOTROPHS; HUMANS; LACTOTROPHS; PARACRINE COMMUNICATION; PITUITARY NEOPLASMS; PROLACTIN; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION; SOMATOSTATIN;

EID: 84862594345     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.10.017     Document Type: Review

References (58)

1. Arzt E., Holsboer F. CRF signaling: molecular specificity for drug targeting in the CNS. Trends Pharmacol. Sci. 2006, 27:531-538.
2. Batista D.L., Zhang X., Gejman R., Ansell P.J., Zhou Y., Johnson S.A., Swearingen B., Hedley-Whyte E.T., Stratakis C.A., Klibanski A. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J. Clin. Endocrinol. Metab. 2006, 91:4482-4488.
3. Brar B.K., Chen A., Perrin M.H., Vale W. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. Endocrinology 2004, 145:1718-1729.
4. Casanueva F.F., Molitch M.E., Schlechte J.A., Abs R., Bonert V., Bronstein M.D., Brue T., Cappabianca P., Colao A., Fahlbusch R., Fideleff H., Hadani M., Kelly P., Kleinberg D., Laws E., Marek J., Scanlon M., Sobrinho L.G., Wass J.A., Giustina A. Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf.) 2006, 65:265-273.
5. Chen Z.P., Xu S., Lightman S.L., Hall L., Levy A. Intracellular calcium ion responses to somatostatin in cells from human somatotroph adenomas. Clin. Endocrinol. (Oxf.) 1997, 46:45-53.
6. Chiodini P.G., Cozzi R., Dallabonzana D., Oppizzi G., Verde G., Petroncini M., Liuzzi A., del Pozo E. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J. Clin. Endocrinol. Metab. 1987, 64:447-453.
7. Cozzi R., Attanasio R., Lodrini S., Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol. (Oxf.) 2004, 61:209-215.
8. Dasen J.S., Rosenfeld M.G. Signaling and transcriptional mechanisms in pituitary development. Annu. Rev. Neurosci. 2001, 24:327-355.
9. Duran-Prado M., Gahete M.D., Martinez-Fuentes A.J., Luque R.M., Quintero A., Webb S.M., Benito-Lopez P., Leal A., Schulz S., Gracia-Navarro F., Malagon M.M., Castano J.P. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J. Clin. Endocrinol. Metab. 2009, 94:2634-2643.
10. Flogstad A.K., Halse J., Grass P., Abisch E., Djoseland O., Kutz K., Bodd E., Jervell J. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J. Clin. Endocrinol. Metab. 1994, 79:461-465.
11. Fredstorp L., Kutz K., Werner S. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Clin. Endocrinol. (Oxf.) 1994, 41:103-108.
12. Fusco A., Gunz G., Jaquet P., Dufour H., Germanetti A.L., Culler M.D., Barlier A., Saveanu A. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur. J. Endocrinol. 2008, 158:595-603.
13. Gazzerro E., Canalis E. Bone morphogenetic proteins and their antagonists. Rev. Endocr. Metab. Disord. 2006, 7:51-65.
14. Giacomini D., Paez-Pereda M., Theodoropoulou M., Labeur M., Refojo D., Gerez J., Chervin A., Berner S., Losa M., Buchfelder M., Renner U., Stalla G.K., Arzt E. Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 2006, 147:247-256.
15. Giacomini D., Paez-Pereda M., Theodoropoulou M., Gerez J., Nagashima A.C., Chervin A., Berner S., Labeur M., Refojo D., Renner U., Stalla G.K., Arzt E. Bone morphogenetic protein-4 control of pituitary pathophysiology. Front Horm. Res. 2006, 35:22-31.
16. Giacomini D., Paez-Pereda M., Stalla J., Stalla G.K., Arzt E. Molecular interaction of BMP-4, TGF-beta, and estrogens in lactotrophs: impact on the PRL promoter. Mol. Endocrinol. 2009, 23:1102-1114.
17. Gillam M.P., Molitch M.E., Lombardi G., Colao A. Advances in the treatment of prolactinomas. Endocr. Rev. 2006, 27:485-534.
18. Grottoli S., Gasco V., Broglio F., Baldelli R., Ragazzoni F., Gallenca F., Mainolfi A., Prodam F., Muccioli G., Ghigo E. Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma. J. Clin. Endocrinol. Metab. 2006, 91:1595-1599.
19. Hofland L.J., van der Hoek J., van Koetsveld P.M., de Herder W.W., Waaijers M., Sprij-Mooij D., Bruns C., Weckbecker G., Feelders R., van der Lely A.J., Beckers A., Lamberts S.W. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J. Clin. Endocrinol. Metab. 2004, 89:1577-1585.
20. Hofland L.J., van der Hoek J., Feelders R., van Aken M.O., van Koetsveld P.M., Waaijers M., Sprij-Mooij D., Bruns C., Weckbecker G., de Herder W.W., Beckers A., Lamberts S.W. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur. J. Endocrinol. 2005, 152:645-654.
21. Hofland L.J., Feelders R.A., de Herder W.W., Lamberts S.W. Pituitary tumours: the sst/D2 receptors as molecular targets. Mol. Cell. Endocrinol. 2011, 326:89-98.
22. Jaquet P., Ouafik L., Saveanu A., Gunz G., Fina F., Dufour H., Culler M.D., Moreau J.P., Enjalbert A. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J. Clin. Endocrinol. Metab. 1999, 84:3268-3276.
23. Kioussi C., Carriere C., Rosenfeld M.G. A model for the development of the hypothalamic-pituitary axis: transcribing the hypophysis. Mech. Dev. 1999, 81:23-35.
24. Labeur M., Paez-Pereda M., Haedo M., Arzt E., Stalla G.K. Pituitary tumors: cell type-specific roles for BMP-4. Mol. Cell. Endocrinol. 2010, 326:85-88.
25. Lamberts S.W., Hofland L.J. Future treatment strategies of aggressive pituitary tumors. Pituitary 2009, 12:261-264.
26. Lamberts S.W., Zweens M., Verschoor L., del Pozo E. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. J. Clin. Endocrinol. Metab. 1986, 63:16-19.
27. Lamberts S.W., Verleun T., Hofland L., Del Pozo E. A comparison between the effects of SMS 201-995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients. Clin. Endocrinol. (Oxf.) 1987, 27:11-23.
28. Liu F., Ventura F., Doody J., Massague J. Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Mol. Cell Biol. 1995, 15:3479-3486.
29. Luini A., Lewis D., Guild S., Corda D., Axelrod J. Hormone secretagogues increase cytosolic calcium by increasing cAMP in corticotropin-secreting cells. Proc. Natl. Acad. Sci. USA 1985, 82:8034-8038.
30. Marzullo P., Ferone D., Di Somma C., Pivonello R., Filippella M., Lombardi G., Colao A. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1999, 1:115-120.
31. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
32. Miyazono K., Kusanagi K., Inoue H. Divergence and convergence of TGF-beta/BMP signaling. J. Cell Physiol. 2001, 187:265-276.
33. Miyoshi T., Otsuka F., Otani H., Inagaki K., Goto J., Yamashita M., Ogura T., Iwasaki Y., Makino H. Involvement of bone morphogenetic protein-4 in GH regulation by octreotide and bromocriptine in rat pituitary GH3 cells. J. Endocrinol. 2008, 197:159-169.
34. Molitch M.E. Pharmacologic resistance in prolactinoma patients. Pituitary 2005, 8:43-52.
35. Nudi M., Ouimette J.F., Drouin J. Bone morphogenic protein (Smad)-mediated repression of proopiomelanocortin transcription by interference with Pitx/Tpit activity. Mol. Endocrinol. 2005, 19:1329-1342.
36. Otani H., Otsuka F., Inagaki K., Suzuki J., Makino H. Roles of bone morphogenetic protein-6 in aldosterone regulation by adrenocortical cells. Acta Med. Okayama 2010, 64:213-218.
37. Otsuka F. Multiple endocrine regulation by bone morphogenetic protein system. Endocr. J. 2010, 57:3-14.
38. Otsuka F., Inagaki K. Unique bioactivities of bone morphogenetic proteins in regulation of reproductive endocrine functions. Reprod. Med. Biol. 2011, 10:131-142.
39. Otsuka F., McTavish K., Shimasaki S. Integral role of GDF-9 and BMP-15 in ovarian function. Mol. Reprod. Dev. 2011, 78:9-21.
40. Paez-Pereda M., Kovalovsky D., Hopfner U., Theodoropoulou M., Pagotto U., Uhl E., Losa M., Stalla J., Grubler Y., Missale C., Arzt E., Stalla G.K. Retinoic acid prevents experimental Cushing syndrome. J. Clin. Invest. 2001, 108:1123-1131.
41. Paez-Pereda M., Giacomini D., Refojo D., Nagashima A.C., Hopfner U., Grubler Y., Chervin A., Goldberg V., Goya R., Hentges S.T., Low M.J., Holsboer F., Stalla G.K., Arzt E. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc. Natl. Acad. Sci. USA 2003, 100:1034-1039.
42. Perrin M.H., Vale W.W. Corticotropin releasing factor receptors and their ligand family. Ann. NY Acad. Sci. 1999, 885:312-328.
43. Puente E., Saint-Laurent N., Torrisani J., Furet C., Schally A.V., Vaysse N., Buscail L., Susini C. Transcriptional activation of mouse sst2 somatostatin receptor promoter by transforming growth factor-beta. Involvement of Smad4. J. Biol. Chem. 2001, 276:13461-13468.
44. Reisine T., Bell G.I. Molecular biology of somatostatin receptors. Endocr. Rev. 1995, 16:427-442.
45. Rossant C.J., Pinnock R.D., Hughes J., Hall M.D., McNulty S. Corticotropin-releasing factor type 1 and type 2alpha receptors regulate phosphorylation of calcium/cyclic adenosine 3',5'-monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase. Endocrinology 1999, 140:1525-1536.
46. Rubinfeld H., Hadani M., Barkai G., Taylor J.E., Culler M.D., Shimon I. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas. J. Clin. Endocrinol. Metab. 2006, 91:2257-2263.
47. Schecterson L.C., McKnight G.S. Role of cyclic adenosine 3',5'-monophosphate-dependent protein kinase in hormone-stimulated beta-endorphin secretion in AtT20 cells. Mol. Endocrinol. 1991, 5:170-178.
48. Scully K.M., Rosenfeld M.G. Pituitary development: regulatory codes in mammalian organogenesis. Science 2002, 295:2231-2235.
49. Shimasaki S., Moore R.K., Erickson G.F., Otsuka F. The role of bone morphogenetic proteins in ovarian function. Reprod. Suppl. 2003, 61:323-337.
50. Shimasaki S., Moore R.K., Otsuka F., Erickson G.F. The bone morphogenetic protein system in mammalian reproduction. Endocr. Rev. 2004, 25:72-101.
51. Shimon I., Yan X., Taylor J.E., Weiss M.H., Culler M.D., Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J. Clin. Invest. 1997, 100:2386-2392.
52. Takano K., Yasufuku-Takano J., Teramoto A., Fujita T. Gi3 mediates somatostatin-induced activation of an inwardly rectifying K+ current in human growth hormone-secreting adenoma cells. Endocrinology 1997, 138:2405-2409.
53. Tsukamoto N., Otsuka F., Miyoshi T., Yamanaka R., Inagaki K., Yamashita M., Otani H., Takeda M., Suzuki J., Ogura T., Iwasaki Y., Makino H. Effects of bone morphogenetic protein (BMP) on adrenocorticotropin production by pituitary corticotrope cells: involvement of up-regulation of BMP receptor signaling by somatostatin analogs. Endocrinology 2010, 151:1129-1141.
54. Tsukamoto N., Otsuka F., Miyoshi T., Inagaki K., Nakamura E., Suzuki J., Ogura T., Iwasaki Y., Makino H. Activities of bone morphogenetic proteins in prolactin regulation by somatostatin analogs in rat pituitary GH3 cells. Mol. Cell. Endocrinol. 2011, 332:163-169.
55. Tsukamoto N., Otsuka F., Miyoshi T., Inagaki K., Nakamura E., Terasaka T., Takeda M., Ogura T., Iwasaki Y., Makino H. Functional interaction of bone morphogenetic protein and growth hormone releasing peptide in adrenocorticotropin regulation by corticotrope cells. Mol. Cell. Endocrinol. 2011, 344:41-50.
56. van der Hoek J., Waaijers M., van Koetsveld P.M., Sprij-Mooij D., Feelders R.A., Schmid H.A., Schoeffter P., Hoyer D., Cervia D., Taylor J.E., Culler M.D., Lamberts S.W., Hofland L.J. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am. J. Physiol. Endocrinol. Metab. 2005, 289:E278-287.
57. Wagenaar A.H., Harris A.G., van der Lely A.J., Lamberts S.W. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinol. (Copenh.) 1991, 125:637-642.
58. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewick R.M., Wang E.A. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242:1528-1534.